About Chronic Constipation (CC)
As many as 26 million Americans suffer from CC. Patients with CC often experience hard and lumpy stools, straining during defecation, a sensation of incomplete evacuation, and fewer than three bowel movements per week. The discomfort of CC significantly affects patients' quality of life by impairing their ability to work and participate in typical daily activities.
Linaclotide is a first-in-class compound currently being tested for the treatment of IBS-C, CC, and other gastrointestinal disorders. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. In preclinical testing linaclotide was shown to increase fluid secretion into the intestine, accelerate intestinal transit, and decrease visceral pain. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. In Phase 2 trials, linaclotide improved bowel function as measured by both complete spontaneous bowel movements and spontaneous bowel movements in patients with CC and IBS-C. Linaclotide is currently being tested for these indications in a pair of Phase 2b trials, which together will enroll 700 patients. A composition of matter patent application is pending for linaclotide, which, if issued would provide protection to 2024, subject to extension.
Microbia (http://www.microbia.com) is an entrepreneurial pharmaceutical
company dedicated to the science and art of great drug-making. Three of the
Company's drug candidates are in clinical studies-linaclotide for the
treatment of IBS-C, CC, and other gastrointestinal disorders; and MD-0727
and MD-3124 for the treatment of hypercholesterolemia. Microbia also has a
growing pipeline of additional drug candidates. Microbia Precision
Engineering, Inc., a majority-owned subsidi
|SOURCE Forest Laboratories, Inc.; Microbia, Inc.|
Copyright©2007 PR Newswire.
All rights reserved